Connection

Ornella Piazza to Humans

Back to Details
This is a "connection" page, showing publications Ornella Piazza has written about Humans.
Ornella Piazza
Connection Strength
0.042
Humans
  1. Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant? Infez Med. 2020 Jun 01; 28(suppl 1):4-5.
    View in: PubMed
    Score: 0.007
  2. Six-minute walk test in pre-operative evaluation of patients for upper abdominal surgery. Eur J Anaesthesiol. 2019 02; 36(2):164-166.
    View in: PubMed
    Score: 0.006
  3. Hepatic encephalopathy and cirrhotic cardiomyopathy in Intensive Care Unit. Minerva Anestesiol. 2018 Aug; 84(8):970-979.
    View in: PubMed
    Score: 0.006
  4. Myocardial injury after non-cardiac surgery: a perioperative affair? Minerva Anestesiol. 2018 Oct; 84(10):1209-1218.
    View in: PubMed
    Score: 0.006
  5. Terlipressin in brain-death donors. Clin Transplant. 2012 Nov-Dec; 26(6):E571-5.
    View in: PubMed
    Score: 0.004
  6. An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). Expert Opin Drug Discov. 2022 01; 17(1):9-18.
    View in: PubMed
    Score: 0.002
  7. COVID-19: a confirmed case of reinfection in a nurse. BMJ Case Rep. 2021 Jul 13; 14(7).
    View in: PubMed
    Score: 0.002
  8. Increase of SARS-CoV-2 RNA load in faecal samples prompts for rethinking of SARS-CoV-2 biology and COVID-19 epidemiology. F1000Res. 2021; 10:370.
    View in: PubMed
    Score: 0.002
  9. Adjunctive IgM-enriched immunoglobulin therapy with a personalised dose based on serum IgM-titres versus standard dose in the treatment of septic shock: a randomised controlled trial (IgM-fat trial). BMJ Open. 2021 02 11; 11(2):e036616.
    View in: PubMed
    Score: 0.002
  10. Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019? Clin Infect Dis. 2020 07 28; 71(15):887-888.
    View in: PubMed
    Score: 0.002
  11. A physiologically-based model to predict individual pharmacokinetics and pharmacodynamics of remifentanil. Eur J Pharm Sci. 2018 Jan 01; 111:20-28.
    View in: PubMed
    Score: 0.001
  12. In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer. Int J Pharm. 2017 Jun 20; 525(2):377-387.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.